Characterization of the CYP2C8 active site by homology modeling

Chemical and Pharmaceutical Bulletin

Volumn 52, Issue 7, 2004, Pages 836-841

  Tanaka, Toshimasa ^a   Kamiguchi, Naomi ^a   Okuda, Teruaki ^a   Yamamoto, Yoshio ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

CYP2C8; CYP3A4; Cytochrome P450; Docking model; Drug drug interaction; Homology modeling

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTIC ACID; CARBAMAZEPINE; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C5; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAPSONE; DICLOFENAC; ESTRADIOL; FLUINDOSTATIN; IBUPROFEN; ISOLEUCINE; LEUCINE; METHADONE; NAPROXEN; OMEPRAZOLE; PACLITAXEL; ROSIGLITAZONE; SERATRODAST; SERINE; TERBINAFINE; TIENILIC ACID; TOLBUTAMIDE; TRIMETHOPRIM; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CRYSTALLOGRAPHY; DRUG HYDROXYLATION; DRUG METABOLISM; HYDROGEN BOND; MOLECULAR MODEL; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; VALIDATION PROCESS; AMINO ACID SEQUENCE; BINDING SITE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; STRUCTURAL HOMOLOGY; VALIDATION STUDY;

AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY;

EID: 16544393904     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.52.836     Document Type: Article

References (34)

1. Bertz R. J., Granneman G. R., Clin. Pharmacokinet., 32, 210-258 (1997).
2. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P., J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
3. Miners J. O., Birkett D. J., Br. J. Clin. Pharmacol., 45, 525-538 (1998).
4. Bertilsson L., Clin. Pharmacokinet., 29, 192-209 (1995).
5. Coller J. K., Somogyi A. A., Bochner F., Xenobiotica, 29, 973-986 (1999).
6. Xu Z. H., Wang W., Zhao X. J., Huang S. L., Zhu B., He N., Shu Y., Liu Z. Q., Zhou H. H., Br. J. Clin. Pharmacol., 48, 416-423 (1999).
7. Bidstrup T. B., Bjornsdottir I., Sidelmann U. G., Thomsen M. S., Hansen K. T., Br. J. Clin. Pharmacol., 56, 305-314 (2003).
8. Monsarrat B., Chatelut E., Royer I., Alvinerie P., Dubois J., Dezeuse A., Roché H., Cros S., Wright M., Canal P., Drug Metab. Dispos., 26, 229-233 (1998).
9. Projean D., Morin P. E., Tu T. M., Ducharme J., Xenobiotica, 33, 841-854 (2003).
10. Kerr B. M., Thummel K. E., Wurden C. J., Klein S. M., Kroetz D. L., Gonzalez F. J., Levy R. H., Biochem. Pharmacol., 47, 1969-1979 (1994).
11. Tracy T. S., Korzekwa K. R., Gonzalez F. J., Wainer I. W., Br. J. Clin. Pharmacol., 47, 545-552 (1999).
12. Becquemont L., Mouajjah S., Escaffre O., Beaune P., Funck-Brentano C., Jaillon P., Drug Metab. Dispos., 27, 1068-1073 (1999).
13. Prueksaritanont T., Ma B., Tang C., Meng Y., Assang C., Lu P., Reider P. J., Lin J. H., Baillie T. A., Br. J. Clin. Pharmacol., 47, 291-298, (1999).
14. Williams P. A., Cosme J., Sridhar V., Johnson E. F., McRee D. E., Mol. Cell, 5, 121-131 (2000).
15. Tanaka T., Okuda T., Yamamoto Y., Chem. Pharm. Bull., 52, 830-835 (2004).
16. Thompson J. D., Higgins D. G., Gibson T. J., Nucleic Acids Res., 22, 4673-4680 (1994).
17. Jones G., Willett P., Glen R. C., Leach A. R., Taylor R., J. Mol. Biol., 267, 727-748 (1997).
18. Rendic S., Drug Metab. Rev., 34, 83-448 (2002).
19. Cresteil T., Monsarrat B., Alvinerie P., Treluyer J. M., Vieira I., Wright M., Cancer Res., 54, 386-392 (1994).
20. Rahman A., Korzekwa K. R., Grogan J., Gonzalez F. J., Harris J. W., Cancer Res., 54, 5543-5546 (1994).
21. Cresteil T., Monsarrat B., Dubois J., Sonnier M., Alvinerie P., Gueritte F., Drug Metab. Dispos., 30, 438-445 (2002).
22. Satoh T., Fujita K. I., Munakata H., Itoh S., Nakamura K., Kamataki T., Itoh S., Yoshizawa I., Anal. Biochem., 286, 179-186 (2000).
23. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J. P., Robinson W. T., Drug Metab. Dispos., 27, 410-416 (1999).
24. Scripture C. D., Pieper J. A., Clin. Pharmacokinet., 40, 263-281 (2001).
25. Karam W. G., Goldstein J. A., Lasker J. M., Ghanayem B. I., Drug Metab. Dispos., 24, 1081-1087 (1996).
26. Ibeanu G. C., Ghanayem B. I., Linko P., Li L., Pederson L. G., Goldstein J. A., J. Biol. Chem., 271, 12496-12501, (1996).
27. Baldwin S. J, Clarke S. E., Chenery R. J., Br. J. Clin. Pharmacol., 48, 424-432 (1999).
28. Kumar G. N., Dubberke E., Rodrigues A. D., Roberts E., Dennisen J. F., Drug Metab. Dispos., 25, 110-115 (1997).
29. Spatzenegger M., Jaeger W., Drug Metab. Rev., 27, 397-417 (1995).
30. Slaughter R. L., Edwards D. J., Pharmacokinetics, 29, 619-624 (1995).
31. Jean P., Lopez-Garcia P., Dansette P., Mansuy D., Goldstein J. L., Eur. J. Biochem., 241, 797-804 (1996).
32. Wildman S. A., Crippen G. M., J. Chem. Inf. Comput. Sci., 39, 868-873 (1999).
33. Williams P. A., Cosme J., Ward A., Angove H. C., Matak Vinkovic D., Jhoti H., Nature (London), 424, 463-468 (2003).
34. Schoch G. A., Yano J. K., Wester M. R., Griffin K. J., Stout C. D., Johnson E. F., J. Biol. Chem., 279, 9497-9503, (2004).